Objective: The Protein Production, Monoclonal Antibody, Tissue Culture Shared Resource (PPSR) supports basic and translational research at UCCC with validated cell lines, preparation of hybridomas, production of monoclonal antibodies, isolation and titering of baculovirus expressing recombinant proteins, and large scale preparation of recombinant proteins and monoclonal antibodies. Services &Technologies: PPSR provides assays pertinent to cancer research, including generation of hybridomas with desired properties to novel antigens, production of monoclonal antibodies, production of recombinant baculovirus that express proteins of interest, large scale cultivation of cells of varying types, and validated tumor cell lines known to be free of contaminants. In FY2010, 74 human tumor cell lines have been validated for use by UCC investigators. The facility has biosafety cabinets, tissue culture incubators, an ELISA plate reader, bioreactors including three GE Wave bioreactors for large scale cultivation of cells, refrigerators, freezers, and liquid nitrogen storage systems for maintaining stocks of cell lines. Consultation &Training: PPSR provides consultation and technical support to help members prepare and isolate hybridomas that produce monoclonal antibodies with the desired properties directed against their proteins of interest. The facility also provides consultation and technical support for preparation, isolation, and production of recombinant baculovirus vectors encoding proteins of interest to support biochemical, molecular, and structural studies by UCCC members, including large volume (0.5 to 10 I) cultures of insect cells producing the protein of interest. Validated tumor cell lines are maintained by the PPSR allowing UCCC investigators to utilize cell lines known to reflect the original tumor cell line, and to be free of contaminating species, in their research. Utilization: PPSR has served 48 UCCC members from all 6 Programs and 3 consortium institutions. The majority of the reagents and cell lines provided by the PPSR support multiple basic and translational projects. Management and Finances: This resource is UCCC-managed. 61% of the operating budget comes from charge backs to UCCC users who represent 76% of the total users. PPSR requests ~$300K CCSG support for 48% of its operating budget. This increase represents the continuation of the cell line validation service currently supported by ARRA funding. Increased funding will continue our ability to meet the needs of the cancer research community to generate and utilize recombinant proteins, monoclonal antibodies, and provide the community with validated tumor cell lines free of contaminants for use in basic and translational research programs.

Public Health Relevance

The Protein Production / Monoclonal Antibody / Tissue Culture Shared Resource provides a centralized services to make cancer-related proteins for UCCC members to study their mechanism of action in identified drugs and cancer-related biomarkers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046934-26
Application #
8616657
Study Section
Subcommittee G - Education (NCI)
Project Start
2014-02-05
Project End
2017-01-31
Budget Start
2014-02-01
Budget End
2015-01-31
Support Year
26
Fiscal Year
2014
Total Cost
$136,832
Indirect Cost
$47,643
Name
University of Colorado Denver
Department
Type
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Saichaemchan, S; Ariyawutyakorn, W; Varella-Garcia, M (2016) Fibroblast Growth Factor Receptors: From the Oncogenic Pathway to Targeted Therapy. Curr Mol Med 16:40-62
Gillen, Austin E; Yamamoto, Tomomi M; Kline, Enos et al. (2016) Improvements to the HITS-CLIP protocol eliminate widespread mispriming artifacts. BMC Genomics 17:338
Justice, Cristina M; Bishop, Kevin; Carrington, Blake et al. (2016) Evaluation of IRX Genes and Conserved Noncoding Elements in a Region on 5p13.3 Linked to Families with Familial Idiopathic Scoliosis and Kyphosis. G3 (Bethesda) 6:1707-12
Eckwahl, Matthew J; Arnion, Helene; Kharytonchyk, Siarhei et al. (2016) Analysis of the human immunodeficiency virus-1 RNA packageome. RNA 22:1228-38
Iguchi, Nao; Malykhina, Anna P; Wilcox, Duncan T (2016) Inhibition of HIF Reduces Bladder Hypertrophy and Improves Bladder Function in Murine Model of Partial Bladder Outlet Obstruction. J Urol 195:1250-6
Seedorf, Gregory; Metoxen, Alexander J; Rock, Robert et al. (2016) Hepatocyte growth factor as a downstream mediator of vascular endothelial growth factor-dependent preservation of growth in the developing lung. Am J Physiol Lung Cell Mol Physiol 310:L1098-110
Agarwal, Neeraj; Dancik, Garrett M; Goodspeed, Andrew et al. (2016) GON4L Drives Cancer Growth through a YY1-Androgen Receptor-CD24 Axis. Cancer Res 76:5175-85
Helfrich, Barbara A; Kim, Jihye; Gao, Dexiang et al. (2016) Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo. Mol Cancer Ther 15:2314-2322
Munson, Daniel J; Egelston, Colt A; Chiotti, Kami E et al. (2016) Identification of shared TCR sequences from T cells in human breast cancer using emulsion RT-PCR. Proc Natl Acad Sci U S A 113:8272-7
Scott, Aaron J; Lieu, Christopher H; Messersmith, Wells A (2016) Therapeutic Approaches to RAS Mutation. Cancer J 22:165-74

Showing the most recent 10 out of 1302 publications